Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

122 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Updated efficacy and safety of entrectinib in NTRK fusion-positive non-small cell lung cancer.
Cho BC, Chiu CH, Massarelli E, Buchschacher GL, Goto K, Overbeck TR, Loong HHF, Chee CE, Garrido P, Dong X, Fan Y, Lu S, Schwemmers S, Bordogna W, Zeuner H, Osborne S, John T. Cho BC, et al. Among authors: massarelli e. Lung Cancer. 2024 Feb;188:107442. doi: 10.1016/j.lungcan.2023.107442. Epub 2023 Dec 15. Lung Cancer. 2024. PMID: 38171156 Free article.
A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer.
De Laurentiis M, Arpino G, Massarelli E, Ruggiero A, Carlomagno C, Ciardiello F, Tortora G, D'Agostino D, Caputo F, Cancello G, Montagna E, Malorni L, Zinno L, Lauria R, Bianco AR, De Placido S. De Laurentiis M, et al. Among authors: massarelli e. Clin Cancer Res. 2005 Jul 1;11(13):4741-8. doi: 10.1158/1078-0432.CCR-04-2569. Clin Cancer Res. 2005. PMID: 16000569 Free article.
Targeting ITGB4/SOX2-driven lung cancer stem cells using proteasome inhibitors.
Guo L, Mohanty A, Singhal S, Srivastava S, Nam A, Warden C, Ramisetty S, Yuan YC, Cho H, Wu X, Li A, Vohra M, Saladi SV, Wheeler D, Arvanitis L, Massarelli E, Kulkarni P, Zeng Y, Salgia R. Guo L, et al. Among authors: massarelli e. iScience. 2023 Jul 10;26(8):107302. doi: 10.1016/j.isci.2023.107302. eCollection 2023 Aug 18. iScience. 2023. PMID: 37554452 Free PMC article.
Erratum: A Non-genetic Mechanism Involving the Integrin β4/Paxillin Axis Contributes to Chemoresistance in Lung Cancer.
Mohanty A, Nam A, Pozhitkov A, Yang L, Srivastava S, Nathan A, Wu X, Mambetsariev I, Nelson M, Subbalakshmi AR, Guo L, Arvanitis LD, Nasser MW, Batra SK, Orban J, Jolly MK, Massarelli E, Kulkarni P, Salgia R. Mohanty A, et al. Among authors: massarelli e. iScience. 2020 Oct 23;23(11):101679. doi: 10.1016/j.isci.2020.101679. eCollection 2020 Nov 20. iScience. 2020. PMID: 33134900 Free PMC article.
Combining radiation and immunotherapy: a new systemic therapy for solid tumors?
Tang C, Wang X, Soh H, Seyedin S, Cortez MA, Krishnan S, Massarelli E, Hong D, Naing A, Diab A, Gomez D, Ye H, Heymach J, Komaki R, Allison JP, Sharma P, Welsh JW. Tang C, et al. Among authors: massarelli e. Cancer Immunol Res. 2014 Sep;2(9):831-8. doi: 10.1158/2326-6066.CIR-14-0069. Cancer Immunol Res. 2014. PMID: 25187273 Free PMC article. Review.
Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing disease.
Zinner RG, Glisson BS, Fossella FV, Pisters KM, Kies MS, Lee PM, Massarelli E, Sabloff B, Fritsche HA Jr, Ro JY, Ordonez NG, Tran HT, Yang Y, Smith TL, Mass RD, Herbst RS. Zinner RG, et al. Among authors: massarelli e. Lung Cancer. 2004 Apr;44(1):99-110. doi: 10.1016/j.lungcan.2003.09.026. Lung Cancer. 2004. PMID: 15013588 Clinical Trial.
Immunotherapy in lung cancer.
Massarelli E, Papadimitrakopoulou V, Welsh J, Tang C, Tsao AS. Massarelli E, et al. Transl Lung Cancer Res. 2014 Feb;3(1):53-63. doi: 10.3978/j.issn.2218-6751.2014.01.01. Transl Lung Cancer Res. 2014. PMID: 25806281 Free PMC article. Review.
Optimal adjuvant therapy in clinically N2 non-small cell lung cancer patients undergoing neoadjuvant chemotherapy and surgery: The importance of pathological response and lymph node ratio.
Shinde A, Horne ZD, Li R, Glaser S, Massarelli E, Koczywas M, Erhunmwunsee L, Reckamp KL, Weksler B, Salgia R, Beriwal S, Amini A. Shinde A, et al. Among authors: massarelli e. Lung Cancer. 2019 Jul;133:136-143. doi: 10.1016/j.lungcan.2019.05.020. Epub 2019 May 19. Lung Cancer. 2019. PMID: 31200820
122 results